VCT220
AssetAlso CX11
Activates GLP-1 receptors to enhance glucose-dependent insulin secretion and reduce appetite.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- GLP1R
- 4
- Indications
- 2
- Trials
- 1
- Developer
Indications
4Obesity
Phase 2, doi.org, 14 Aug 2026
Overweight
Phase 2, doi.org, 14 Aug 2026
Type 2 diabetes
Phase 2, Not yet recruiting, NCT07872436, clinicaltrials.gov, 15 Oct 2026
1 more
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials2
- Evidence for its targets2
- Competitors12
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.